Evidence for grey matter MTR abnormality in minimally disabled patients with early relapsing-remitting multiple sclerosis

Abstract

In early RRMS, grey matter MTR abnormality is apparent. The correlation with mild clinical impairment (in this essentially non-disabled cohort) suggests that NAGM MTR could be a clinically relevant surrogate marker in therapeutic trials.